Study of treatment outcome of patients of tuberculous cervical lymphedenopathy

Results Total patients examined: 117, in the age group 10-70 years (mean age 40). Females affected – 89 (76.07%), Males 28 (23.93%). Most common age group affected (M/F): 15-20 years: 37 (31.63%) patients. Biopsy was done in 73 patients (62.39%). Patients received Category1ATT under RNTCP. After 6 months of therapy, 22 patients (18.81%) stopped treatment in view of nonpalpable mass. Out of remaining 95 patients (81.19%), 14 patients’ (11.96%) lymph node size increased with slow regression, 17 patients’ (14.52%) liquefaction and repeated aspiration was done, 57 patients’ (48.72%) lymph node size showed regression less than 50%, 7 patients (5.98%) came up with new group of lymph nodes with size gradually increased. For all 95 patients, therapy was extended (continuation phase) for 2-3 months. 7 patients received ATT for 12 months. Conclusion Extrapulmonary tuberculosis like tuberculous lymphadenopathy is benefited with extension of anti tuberculosis treatment.